Thursday, August 2, 2018

Bitcoin Begins Attempt To Break Above This Down Trend Line

&l;p&g;&l;img class=&q;dam-image shutterstock size-large wp-image-1139258804&q; src=&q;https://specials-images.forbesimg.com/dam/imageserve/1139258804/960x0.jpg?fit=scale&q; data-height=&q;639&q; data-width=&q;960&q;&g; Shutterstock

Bitcoin&s;s wall of worry is quite different than the stock market&s;s wall of worry. The equity world is concerned with the effects on earnings of interest rates, the price of oil and the latest thinking of the current White House occupant.

With the crypto-currencies, all of that is interesting and ultimately relevant, but the main concerns lie elsewhere: especially in the emerging regulatory framework that&s;s developing.

For example, the U.S. Chamber of Commerce wants &q;regulatory clarity&q; in the bitcoin world, according to Forbes contributor Aaron Stanley &l;a href=&q;https://www.forbes.com/sites/astanley/2018/07/22/u-s-chamber-calls-for-regulatory-clarity-on-cryptocurrencies-initial-coin-offerings/#6db0cf4b726e&q;&g;right here&l;/a&g;.

The regulation of tokenized securities is an issue, as Forbes contributor Andrea Tinianow explains &l;a href=&q;https://www.forbes.com/sites/andreatinianow/2018/07/04/tokenized-securities-are-not-secured-by-delaware-blockchain-amendments/#1b937e853e79&q;&g;here&l;/a&g;.

In Malta, government authorities are putting together the first-in-the-world official regulations for crypto, block chain and DLT, as noted by Forbes contributor Rachel Wolfson &l;a href=&q;https://www.forbes.com/sites/rachelwolfson/2018/07/05/maltese-parliament-passes-laws-that-set-regulatory-framework-for-blockchain-cryptocurrency-and-dlt/#3124a48849ed&q;&g;right here&l;/a&g;.

Buyers seem to approve of the increasing regulatory focus -- at least they did last week. Bitcoin&s;s first real attempt to climb back up that wall of worry is taking place now, as you can see if you closely examine this monthly price chart:

&l;img class=&q;size-full wp-image-3868&q; src=&q;http://blogs-images.forbes.com/johnnavin/files/2018/07/Bitcoin-index-monthly-7-22-18-1.jpg?width=960&q; alt=&q;&q; data-height=&q;928&q; data-width=&q;1240&q;&g; NYSE Bitcoin Index monthly chart.

That price bar for July, representing the highs and lows, closed at the top end of the bar and is pushing slightly up above the downtrend line. That&s;s the red dotted line that connects the December, 2017 peak with the much lower May, 2018 peak. Bitcoin bulls would like to see the price move above that line and stay there by month&s;s end as evidence that the trend downward had ended.

Here&s;s the weekly chart where the movement is a bit clearer:

&l;img class=&q;size-full wp-image-3870&q; src=&q;http://blogs-images.forbes.com/johnnavin/files/2018/07/Bitcoin-index-weekly-7-22-18.jpg?width=960&q; alt=&q;&q; data-height=&q;928&q; data-width=&q;1240&q;&g; NYSE Bitcoin Index weekly chart.

Here you can see that price has moved above the downward trend line without question. The MACD technical indicator below the actual price chart -- representing a comparison of moving average to price -- may be about to give a bullish signal. I&s;ve circled in red where the indicator&s;s black line may cross above the red line. If that takes place, it&s;s likely that an uptrend is underway, according to chart reading textbooks.

This chart&a;nbsp;is based on the daily price and gives an even closer view:

&l;img class=&q;size-full wp-image-3872&q; src=&q;http://blogs-images.forbes.com/johnnavin/files/2018/07/Bitcoin-index-daily-7-22-18.jpg?width=960&q; alt=&q;&q; data-height=&q;928&q; data-width=&q;1240&q;&g; NYSE Bitcoin Index daily chart.

Again, you can see clearly how the down trend line has been taken out by the price breaking upward against it and above it. The MACD technical indicator is confirming the action by showing an upward slant that diverges from the 3 recent price lows, each one a bit lower than the previous one. The next step, from a bull&s;s perspective, would be to see the price rise above the down trending Ichimoku cloud just above it.

And this one is the 5-minute price from early Sunday night:

&l;img class=&q;size-full wp-image-3875&q; src=&q;http://blogs-images.forbes.com/johnnavin/files/2018/07/Bitcoin-5-minute-7-22-18-5p-ET.jpg?width=960&q; alt=&q;&q; data-height=&q;340&q; data-width=&q;964&q;&g; Bitcoin 5-minute chart, 7/22/18 pm.

It looks as if the wall of worry is slowly being ascended for bitcoin -- at least for now. Nothing is guaranteed, of course, and the constantly changing regulatory environment is always subject to the actions of government officials and politicians.

&l;em&g;I do not hold positions in these investments.&a;nbsp;No recommendations are made by me one way or the other.&a;nbsp;&a;nbsp;If you&s;re an investor, you&s;d want to look much deeper into each of these situations. You can lose money trading or investing in stocks. Always do your own independent research, due diligence and seek professional advice from a licensed investment advisor.&l;/em&g;

&a;nbsp;

&a;nbsp;

&a;nbsp;&l;/p&g;

Tuesday, July 31, 2018

Chick-fil-A moo-ving on from its Cow Calendar

The Cow Calendar is finally�getting creamed.

Chick-fil-A announced that after 20 years, it will�retire�the popular, promotional�Cow Calendar to "greener pastures."

"We have made the difficult decision to retire our annual Cow Calendars at the end of 2018," Chick-fil-A posted on its website. "We will continue our commitment to take care of customers and offer new ways for you to interact with Chick-fil-A."

But it wasn't�just the actual wall calendar filled with photos of the company's iconic ��Eat Mor Chikin�� cows that was�popular among fans. Rather, it was the monthly free food offers it contained.�

More: Texas baby born in a Chick-fil-A bathroom to get free food for life, plus a guaranteed job

The 2018 calendar, which went on sale last November at participating locations nationwide, cost $8 and included a card loaded with freebies like free fries, soda, nuggets, sandwiches and mystery offers.

The offers in the calendar have an estimated value of at least $30.

Best known for its chicken sandwiches, the company named�America's favorite fast-food chain�in a recent survey has featured cows in its advertising for the last 23 years.�Its running joke has cows plugging Chick-fil-A as a way of preserving their own lives because customers will eat more chicken and less beef.

According to an email the company sent to customers, the calendar has reached "retirement age �� in cow years, of course."�

"It��s a bittersweet occasion as we celebrate the past 20 years of steers and say goodbye to a beloved bovine tradition at the end of 2018," the email said.

Udderly disappointed fans are taking to social media.

No @ChickfilA - NOOOOOO! The #CowCalendar is no more. Say it ain��t so Cows. ��� pic.twitter.com/IrXznaxoM9

— Brian Binette (@BrianBinette) July 18, 2018

��No @ChickfilA - NOOOOOO! The #CowCalendar is no more. Say it ain��t so Cows,�� Brian Binette tweeted.

EXCUSE ME @ChickfilA but ��retiring�� the cow calendar is NOT OKAY!! It��s unfair that my children will have to grow up in a world without cow calendars and I��m mad about it. #CowCalendar#ChickfilA

— audra kate (@akmo1226) July 18, 2018

"EXCUSE ME @ChickfilA but ��retiring�� the cow calendar is NOT OKAY!! It��s unfair that my children will have to grow up in a world without cow calendars and I��m mad about it,"� Twitter user Audra Kate wrote.

@ChickfilA stopping the cow calendar may be the saddest thing that has happened all year! #chickfila#cowcalendar#bringthecowsback#eatmorchickeb

— lindsay Yessa (@loulouyessa) July 18, 2018

"@ChickfilA stopping the cow calendar may be the saddest thing that has happened all year!�Twitter user Lindsay Yessa���tweeted.

A group calling themselves the "Association of Cow Calendar Admirers" started a Change.org petition asking Chick-fil-A to reconsider the move.�

"Everyone in America, from the child hoping for a free nugget entree the next month, to the calendar collecting aficionado will feel this loss in their heart," the petition reads. "We need the Cow Calendar. We need the brief moments of comedic joy it brings in a further connecting and frightening world."

More: Top fast-food, full-service restaurants for customer satisfaction named in new ACSI survey

More: Starbucks' 'Signing Store' will let deaf customers order using sign language

More: This mom eating Chick-fil-A during her maternity shoot is everything

CLOSE

This is so genius. Time

Chick-fil-A said in an email to customers that it is updating the�Chick-fil-A One smartphone app�in anticipation�of the calendar's retirement. With the app, customers can earn freebies and place orders.

"Very soon, you��ll have a lot more chances to redeem delicious free food rewards using the new-and-improved Chick��fil��A One," the email said.

Acknowledging the calendars were a popular holiday gift, the company said it will step up its "gift card game to make sure you have something to give those most special to you."

Kelly Tyko is a consumer columnist and retail reporter for Treasure Coast Newspapers and�TCPalm.com, part of the USA TODAY NETWORK. Read her Bargainista tips at�TCPalm.com/Bargainista,�follow her on Twitter @KellyTyko�and email her at kelly.tyko@tcpalm.com.�Sign up for her weekly newsletter at�www.tcpalm.com/featured-newsletter/bargainistabest.�

Wednesday, July 25, 2018

State of Alaska Department of Revenue Cuts Stake in Weingarten Realty Investors (WRI)

State of Alaska Department of Revenue trimmed its position in Weingarten Realty Investors (NYSE:WRI) by 7.8% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 70,653 shares of the real estate investment trust’s stock after selling 6,007 shares during the period. State of Alaska Department of Revenue’s holdings in Weingarten Realty Investors were worth $2,175,000 at the end of the most recent quarter.

Several other institutional investors have also recently modified their holdings of the company. Flinton Capital Management LLC lifted its holdings in shares of Weingarten Realty Investors by 29.9% in the fourth quarter. Flinton Capital Management LLC now owns 8,192 shares of the real estate investment trust’s stock valued at $269,000 after purchasing an additional 1,888 shares in the last quarter. Hsbc Holdings PLC lifted its holdings in shares of Weingarten Realty Investors by 8.1% in the first quarter. Hsbc Holdings PLC now owns 26,148 shares of the real estate investment trust’s stock valued at $734,000 after purchasing an additional 1,960 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of Weingarten Realty Investors by 3.6% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 62,758 shares of the real estate investment trust’s stock valued at $1,762,000 after purchasing an additional 2,160 shares in the last quarter. Daiwa Securities Group Inc. increased its position in shares of Weingarten Realty Investors by 17.8% in the first quarter. Daiwa Securities Group Inc. now owns 15,200 shares of the real estate investment trust’s stock valued at $427,000 after acquiring an additional 2,300 shares during the last quarter. Finally, Meadow Creek Investment Management LLC increased its position in shares of Weingarten Realty Investors by 29.9% in the fourth quarter. Meadow Creek Investment Management LLC now owns 11,264 shares of the real estate investment trust’s stock valued at $370,000 after acquiring an additional 2,596 shares during the last quarter. Institutional investors own 77.15% of the company’s stock.

Get Weingarten Realty Investors alerts:

NYSE:WRI opened at $30.25 on Friday. The company has a debt-to-equity ratio of 1.01, a quick ratio of 2.08 and a current ratio of 2.08. The stock has a market capitalization of $3.86 billion, a P/E ratio of 12.35, a P/E/G ratio of 3.63 and a beta of 0.54. Weingarten Realty Investors has a 52-week low of $25.67 and a 52-week high of $33.83.

Weingarten Realty Investors (NYSE:WRI) last released its earnings results on Tuesday, April 24th. The real estate investment trust reported $0.29 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.57 by ($0.28). The company had revenue of $132.45 million during the quarter, compared to analyst estimates of $131.46 million. Weingarten Realty Investors had a net margin of 80.74% and a return on equity of 24.66%. Weingarten Realty Investors’s revenue was down 7.8% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.61 EPS. analysts anticipate that Weingarten Realty Investors will post 2.31 earnings per share for the current year.

A number of analysts recently issued reports on the company. ValuEngine downgraded Weingarten Realty Investors from a “hold” rating to a “sell” rating in a research report on Monday, July 2nd. Zacks Investment Research raised Weingarten Realty Investors from a “sell” rating to a “hold” rating in a research report on Thursday, April 26th. TheStreet raised Weingarten Realty Investors from a “c+” rating to a “b-” rating in a research report on Monday, June 25th. Boenning Scattergood reaffirmed a “hold” rating on shares of Weingarten Realty Investors in a research report on Thursday, April 26th. Finally, JPMorgan Chase & Co. lowered their target price on Weingarten Realty Investors from $31.00 to $29.00 and set a “neutral” rating on the stock in a research report on Thursday, April 26th. One analyst has rated the stock with a sell rating, seven have issued a hold rating and four have given a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus target price of $31.17.

Weingarten Realty Investors Profile

Weingarten Realty Investors (NYSE: WRI) is a shopping center owner, manager and developer. At December 31, 2017, the Company owned or operated under long-term leases, either directly or through its interest in real estate joint ventures or partnerships, a total of 204 properties which are located in 17 states spanning the country from coast to coast.

Recommended Story: Earnings Per Share (EPS) Explained

Want to see what other hedge funds are holding WRI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Weingarten Realty Investors (NYSE:WRI).

Institutional Ownership by Quarter for Weingarten Realty Investors (NYSE:WRI)

Saturday, July 21, 2018

Top 10 Value Stocks To Buy For 2019

tags:TSBK,ELGX,SFS,TROX,FLXS,SRCE,ZSAN,WMS,VDTH,PEN,

Enterprise GP Holdings L.P. common stock (NYSE:EPE)’s share price was down 1.7% during trading on Tuesday following insider selling activity. The stock traded as low as $2.40 and last traded at $2.38. Approximately 28,073 shares were traded during mid-day trading, a decline of 98% from the average daily volume of 1,140,837 shares. The stock had previously closed at $2.42.

Specifically, major shareholder Apollo Investment Fund Vii L. P sold 416,054 shares of the stock in a transaction on Monday, July 9th. The stock was sold at an average price of $2.94, for a total transaction of $1,223,198.76. The sale was disclosed in a filing with the SEC, which is available through this link. Also, major shareholder Apollo Management Holdings Gp, sold 285,000 shares of the stock in a transaction on Friday, June 29th. The shares were sold at an average price of $3.06, for a total value of $872,100.00. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 2,037,073 shares of company stock valued at $6,026,627. 0.39% of the stock is owned by corporate insiders.

Top 10 Value Stocks To Buy For 2019: Timberland Bancorp Inc.(TSBK)

Advisors' Opinion:
  • [By Shane Hupp]

    Timberland Bancorp, Inc. (NASDAQ:TSBK) declared a None dividend on Tuesday, April 24th, Zacks reports. Investors of record on Friday, May 11th will be paid a dividend of 0.23 per share by the savings and loans company on Friday, May 25th. This represents a dividend yield of 1.61%. The ex-dividend date is Thursday, May 10th.

  • [By Ethan Ryder]

    Press coverage about Timberland Bancorp (NASDAQ:TSBK) has trended somewhat positive on Friday, according to Accern Sentiment Analysis. Accern ranks the sentiment of press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Timberland Bancorp earned a daily sentiment score of 0.01 on Accern’s scale. Accern also gave media coverage about the savings and loans company an impact score of 46.0053181885204 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

Top 10 Value Stocks To Buy For 2019: Endologix, Inc.(ELGX)

Advisors' Opinion:
  • [By Stephan Byrd]

    Endologix (NASDAQ:ELGX) was upgraded by investment analysts at ValuEngine from a “strong sell” rating to a “sell” rating in a research report issued on Wednesday.

  • [By Ethan Ryder]

    Here are some of the news headlines that may have impacted Accern’s analysis:

    Get Endologix alerts: Endologix Reports Positive One-Year Results From the Ovation LUCY Study (dicardiology.com) Endologix, Inc. to Announce Second Quarter 2018 Financial Results on August 9, 2018 (finance.yahoo.com) Stock Under Active Eyes: Endologix, Inc. (ELGX) (bitcoinpriceupdate.review) Endologix, Inc. (ELGX) Given Consensus Recommendation of “Hold” by Brokerages (americanbankingnews.com) Endologix Inc. to Post FY2016 Revenue of ($0.71) Per Share, Leerink Swann Forecasts (ELGX) (bharatapress.com)

    NASDAQ:ELGX traded down $0.09 on Tuesday, hitting $5.42. 4,339 shares of the stock were exchanged, compared to its average volume of 483,122. The firm has a market capitalization of $462.06 million, a PE ratio of -11.31 and a beta of 0.44. The company has a debt-to-equity ratio of 3.58, a current ratio of 2.13 and a quick ratio of 1.37. Endologix has a fifty-two week low of $3.75 and a fifty-two week high of $6.72.

Top 10 Value Stocks To Buy For 2019: Smart(SFS)

Advisors' Opinion:
  • [By Brian Stoffel]

    But over the past five years, the industry has been turned upside down by changes in business models, a focus on delivery, and mass consolidation. While the dust is far from settled, here are 10 of the largest publicly traded grocers you can buy stock in.

    Company Market Cap Stores Regions Chains Amazon (NASDAQ:AMZN) $780 billion 500 USA Whole Foods Walmart (NYSE:WMT) $250 billion 11,700 Worldwide Walmart Costco (NASDAQ:COST) $86 billion 750 USA Costco Kroger (NYSE:KR) $21 billion 2,800 USA Kroger, Roundy's, Ralph's, Food 4 Less Sprouts (NASDAQ: SFM) $3 billion 300 Western and Southern U.S. Sprouts Farmer's Market Weis Market (NYSE: WMK) $1.3 billion 200 Mid-Atlantic U.S. Weis Market SUPERVALU�(NYSE: SVU) $630 million 100 Midwestern U.S. Cub Foods, Shopper's Food, Hornbacher Ingles Market�(NASDAQ: IMKTA) $580 million 200 Southeastern U.S. Ingles Market, Sav-Mor Smart & Final�(NYSE: SFS) $360 million 350 Western U.S. Smart & Final, Cash & Carry Natural Grocers (NYSE: NGVC) $230 million 150 Western U.S. Natural Grocers

    Data source: Yahoo! Finance, company websites.

  • [By Shane Hupp]

    Smart & Final (NYSE: SFS) and Kroger (NYSE:KR) are both consumer staples companies, but which is the better business? We will compare the two companies based on the strength of their dividends, institutional ownership, profitability, earnings, analyst recommendations, valuation and risk.

  • [By Joseph Griffin]

    ValuEngine lowered shares of Smart & Final Stores (NYSE:SFS) from a sell rating to a strong sell rating in a research report released on Wednesday.

  • [By Lisa Levin]

     

    Losers Heat Biologics, Inc. (NASDAQ: HTBX) shares tumbled 48.59 percent to close at $1.275 on Thursday after the company priced its $18,000,000 public offering. InVivo Therapeutics Holdings Corp. (NASDAQ: NVIV) fell 38.77 percent to close at $8.26 on Thursday. Check-Cap Ltd. (NASDAQ: CHEK) shares tumbled 27.43 percent to close at $8.81. Achaogen, Inc. (NASDAQ: AKAO) dropped 24.76 percent to close at $11.06 in reaction to a disappointing update from an FDA AdCom panel. The FDA panel voted favorably for the company's Plazcomicin for treatment of adults with complicated urinary tract infections, but also voted against the therapy to be used as a treatment for bloodstream infections. Anika Therapeutics, Inc. (NASDAQ: ANIK) shares declined 24.68 percent to close at $34.80 after the company posted downbeat quarterly results. LSC Communications, Inc. (NASDAQ: LKSD) shares fell 24.22 percent to close at $12.64 following wider-than-expected Q1 loss. Cardinal Health, Inc. (NYSE: CAH) fell 21.42 percent to close at $50.80 following downbeat quarterly profit. Horizon Global Corporation (NYSE: HZN) dropped 20.42 percent to close at $6.00 following downbeat quarterly earnings. Hornbeck Offshore Services, Inc. (NYSE: HOS) slipped 20.11 percent to close at $2.90 following wider-than-expected Q1 loss. Esperion Therapeutics, Inc. (NASDAQ: ESPR) fell 19.28 percent to close at $36.93. Esperion Therapeutics stock lost roughly a third of its value Wednesday after the company reported mixed Phase III results for its leading drug candidate, bempedoic acid. JP Morgan downgraded Esperion Therapeutics from Neutral to Underweight. Laredo Petroleum, Inc. (NYSE: LPI) declined 17.77 percent to close at $8.98 after the company reported weaker-than-expected Q1 earnings. The Habit Restaurants, Inc. (NASDAQ: HABT) dipped 16.1 percent to close at $8.60 after the company reported downbeat quarterly results. Arcadia Biosciences, Inc. (N

Top 10 Value Stocks To Buy For 2019: Tronox Limited(TROX)

Advisors' Opinion:
  • [By Stephan Byrd]

    Hydrogenics (NASDAQ: HYGS) and Tronox (NYSE:TROX) are both oils/energy companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, valuation, institutional ownership, dividends, risk, analyst recommendations and earnings.

Top 10 Value Stocks To Buy For 2019: Flexsteel Industries, Inc.(FLXS)

Advisors' Opinion:
  • [By Logan Wallace]

    Hooker Furniture (NASDAQ: HOFT) and Flexsteel Industries (NASDAQ:FLXS) are both small-cap consumer discretionary companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, analyst recommendations, dividends, risk, earnings, valuation and institutional ownership.

  • [By Shane Hupp]

    BidaskClub cut shares of Flexsteel Industries (NASDAQ:FLXS) from a hold rating to a sell rating in a research report released on Friday morning.

    Separately, ValuEngine lowered shares of Flexsteel Industries from a hold rating to a sell rating in a research report on Friday, April 27th.

Top 10 Value Stocks To Buy For 2019: 1st Source Corporation(SRCE)

Advisors' Opinion:
  • [By Ethan Ryder]

    Get a free copy of the Zacks research report on 1st Source (SRCE)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Max Byerly]

    1st Source (NASDAQ:SRCE)’s share price hit a new 52-week high and low during mid-day trading on Thursday . The stock traded as low as $56.13 and last traded at $55.94, with a volume of 100 shares changing hands. The stock had previously closed at $55.94.

  • [By Max Byerly]

    1st Source Co. (NASDAQ:SRCE) has been assigned a consensus rating of “Hold” from the six analysts that are presently covering the stock, Marketbeat.com reports. Four analysts have rated the stock with a hold rating and two have given a buy rating to the company. The average 12 month target price among analysts that have covered the stock in the last year is $55.00.

Top 10 Value Stocks To Buy For 2019: Zosano Pharma Corporation(ZSAN)

Advisors' Opinion:
  • [By Joseph Griffin]

    Zosano Pharma (NASDAQ:ZSAN) will announce its earnings results after the market closes on Tuesday, May 15th.

    Zosano Pharma (NASDAQ:ZSAN) last issued its quarterly earnings results on Monday, March 12th. The biotechnology company reported ($3.80) EPS for the quarter, topping analysts’ consensus estimates of ($4.80) by $1.00.

  • [By Paul Ausick]

    Zosano Pharma Corp. (NASDAQ: ZSAN) dropped about 17% Tuesday to post a new 52-week low of $0.54 after closing at $0.65 on Friday. Volume was around 720,000, about 10% below the daily average of around 850,000. The company had no specific news.

Top 10 Value Stocks To Buy For 2019: Advanced Drainage Systems, Inc.(WMS)

Advisors' Opinion:
  • [By Lisa Levin] Companies Reporting Before The Bell Booz Allen Hamilton Holding Corporation (NYSE: BAH) is estimated to report quarterly earnings at $0.46 per share on revenue of $1.67 billion. Momo Inc. (NASDAQ: MOMO) is projected to report quarterly earnings at $0.5 per share on revenue of $396.17 million. Multi-Color Corporation (NASDAQ: LABL) is expected to report quarterly earnings at $1.06 per share on revenue of $424.96 million. American Woodmark Corporation (NASDAQ: AMWD) is estimated to report quarterly earnings at $1.15 per share on revenue of $382.4 million. The Bank of Nova Scotia (NYSE: BNS) is projected to report quarterly earnings at $1.32 per share on revenue of $5.46 billion. Jianpu Technology Inc. (NYSE: JT) is expected to report quarterly loss at $0.04 per share on revenue of $47.51 million. Trans World Entertainment Corporation (NASDAQ: TWMC) is estimated to report earnings for its first quarter. Advanced Drainage Systems, Inc. (NYSE: WMS) is estimated to report quarterly loss at $0.06 per share on revenue of $249.44 million. Quotient Limited (NASDAQ: QTNT) is expected to report quarterly loss at $0.48 per share on revenue of $5.73 million. Elbit Systems Ltd. (NASDAQ: ESLT) is projected to report earnings for its first quarter. Evogene Ltd. (NASDAQ: EVGN) is expected to report earnings for its first quarter.

     

  • [By Stephan Byrd]

    Advanced Drainage Systems (NYSE:WMS) had its target price hoisted by equities researchers at Robert W. Baird from $29.00 to $32.00 in a report issued on Wednesday. The firm currently has an “outperform” rating on the construction company’s stock. Robert W. Baird’s price target points to a potential upside of 10.15% from the company’s previous close.

  • [By Motley Fool Staff]

    Advanced Drainage Systems (NYSE:WMS) Q4 2018 Earnings Conference CallMay. 29, 2018 10:00 a.m. ET

    Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks:

    Operator

Top 10 Value Stocks To Buy For 2019: Videocon d2h Limited(VDTH)

Advisors' Opinion:
  • [By Logan Wallace]

    Videocon d2h (NASDAQ: VDTH) and MSG Networks (NYSE:MSGN) are both small-cap consumer discretionary companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, valuation, risk, earnings and institutional ownership.

  • [By Joseph Griffin]

    Videocon d2h (NASDAQ: VDTH) and DISCOVERY COMMUNICATIONS INC. Common Stock (NASDAQ:DISCA) are both consumer discretionary companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, analyst recommendations, risk, profitability and earnings.

Top 10 Value Stocks To Buy For 2019: Penumbra, Inc.(PEN)

Advisors' Opinion:
  • [By Stephan Byrd]

    Penumbra (NYSE:PEN) released its quarterly earnings results on Tuesday. The company reported $0.06 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.02) by $0.08, Fidelity Earnings reports. Penumbra had a return on equity of 1.15% and a net margin of 3.65%. The business had revenue of $102.70 million for the quarter, compared to analysts’ expectations of $90.98 million. During the same quarter in the previous year, the firm posted ($0.10) earnings per share. The company’s revenue was up 40.3% compared to the same quarter last year.

  • [By Logan Wallace]

    Penumbra (NYSE:PEN) Director Bridget O’rourke purchased 700 shares of the business’s stock in a transaction that occurred on Friday, May 25th. The stock was bought at an average cost of $156.40 per share, for a total transaction of $109,480.00. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Monday, July 16, 2018

MoviePass News: 3D, IMAX Movies Added (for a Fee)

In the latest MoviePass news, the company announced that its subscribers will have the option of watching 3D and IMAX movies as well for an additional fee.

MoviePass News Source: Wikipedia

The moviegoing subscriber provider — which is owned by publicly-traded Helios and Matheson Analytics (NASDAQ:HMNY) — is hoping to invite more people back to movie theaters at a time when online streaming services are dominating and less people are actually getting out of the house and visiting a cinema.

MoviePass CEO Mitch Lowe said that starting on Labor Day, on September 3rd, the app will offer a feature that will allow its subscribers to add IMAX and 3D movies for an additional $2 to $5 a month. “Imagine you’re a customer and now you can go to what typically might be a $17 or $18 ticket for an extra $5?” Lowe explained to Business Insider. “That’s going to be extremely valuable.”

The monthly fee would still only add up to a little bit more than the full price or perhaps even less of a 3D or IMAX ticket in an expensive city such as New York where movie tickets sometimes exceed $20 if you’re going for these films. The additional fee is a one-time fee that’s added on to the current price of $10 per month.

HMNY stock was down about 9.8% early on Friday afternoon despite the news.

Compare Brokers

Wednesday, July 11, 2018

3 Reasons MoviePass Stock Is No Sirius XM Radio

Things are getting pretty dire in the world of�Helios and Matheson Analytics�(NASDAQ:HMNY), the reeling parent company of the MoviePass multiplex subscription service. The stock has surrendered 97% of its value in 2018, and there doesn't seem to be an easy way out.

Optimists may want to look at Sirius XM Radio (NASDAQ:SIRI) for inspiration at this point. Helios and Matheson may be trading for pocket change now, but Sirius XM stock bottomed out at $0.05 in early 2009, and there other similarities beyond the penny stock pricing.

Sirius XM was hemorrhaging money at that point. The satellite radio provider had just completed a potentially game-changing acquisition, but it was warning that it was on the brink of filing for bankruptcy reorganization. Sirius XM also blew up its outstanding share count in an mad-dash effort to raise money to stay afloat, just as Helios and Matheson is doing right now. MoviePass may be popular, but there are a few reasons why it's not the second coming of Sirius XM, a stock that would go on to become a scintillating 140-bagger after bottoming out at a nickel.

MoviePass and iHeartRadio at a promotional event in March.

Image source: MoviePass.

1. Sirius XM got a life-changing capital infusion

Sirius XM was running out of money, but it had a pair of media moguls willing to step up with a financial lifeline. Sirius XM chose to go with John Malone's offer. Sirius XM was desperate. It handed Malone a 40% preferred share stake in exchange for a $530 million loan that it would have to repay at 15% interest.�

It wasn't pretty -- and it was another step in dramatically expanding the share count -- but it was what Sirius XM needed at the time. The problem with Helios and Matheson is that there aren't a lot of sugar daddies likely waiting in the wings.�

A multiplex operator isn't going to step up because MoviePass devalues their product. With 3 million premium subscribers, MoviePass has value, but likely not enough to drum up the interest from acquirers that could actually make the most of the MoviePass platform. Even if there was a company with deep pockets eager to help, the model itself could be a deal breaker.�

2. Sirius XM turned profitable�

Sirius XM was able to post positive net income within a couple of quarters of bottoming out, and it's pretty much been that way ever since. There is no reason to believe that MoviePass will be profitable anytime soon.

Sirius XM operates a model where the fixed income costs are high but the variable rates are low. Once it hit a point where scalability would kick in, it was easy to see where the bottom line would grow exponentially. MoviePass is the other way around. The company pays retail prices for most of the movie tickets it subsidizes, so it spends a lot more than $9.95 a month on tickets. Variable costs are high, and gross margin will continue to be negative at current price points.�

Sirius XM had a compelling business model, and that made it easy to raise money. Helios and Matheson won't be so lucky.

3. MoviePass doesn't have pricing elasticity

Sirius XM has been able to consistently grow its subscriber count, and that's with the music royalty fees that it passes on to listeners inching higher with every passing year. MoviePass is going to be a hard sell outside of $9.95 a month. There were just 20,000 subscribers last summer when the service cost most accounts $29.95 a month. The spike to 3 million has come as a result of the value proposition.�

It's not a sustainable value proposition for MoviePass, and it's rolling out surge pricing -- making folks pay a bit more to view movies during peak levels. This could be the beginning of the end for MoviePass, and it comes at a time when actual exhibitors -- the multiplix operators that can actually turn a profit by discounting ticket sales -- are�beefing up their rival offerings.�

MoviePass is in a pickle. If it raises its price it will lose subscribers, particularly the light users that it needs to offset the heavy eaters of its celluloid buffet. Adding new fees and restrictive conditions will have the same effect.�

Sirius XM and MoviePass are entertainment subscription services, but only one of them has shown the ability to offer its platform sustainably for the long haul. Helios and Matheson is going to need a model overhaul to stay afloat at this point.

Sunday, June 24, 2018

Contrasting Basf (BASFY) and FMC (FMC)

FMC (NYSE: FMC) and Basf (OTCMKTS:BASFY) are both large-cap basic materials companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, dividends, valuation, profitability, earnings and institutional ownership.

Profitability

Get FMC alerts:

This table compares FMC and Basf’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
FMC 26.54% 22.69% 7.14%
Basf 9.42% 17.83% 7.86%

Analyst Recommendations

This is a summary of recent ratings for FMC and Basf, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
FMC 0 2 15 0 2.88
Basf 0 4 2 0 2.33

FMC presently has a consensus price target of $100.35, indicating a potential upside of 15.89%. Given FMC’s stronger consensus rating and higher possible upside, research analysts plainly believe FMC is more favorable than Basf.

Risk & Volatility

FMC has a beta of 1.63, suggesting that its stock price is 63% more volatile than the S&P 500. Comparatively, Basf has a beta of 1.16, suggesting that its stock price is 16% more volatile than the S&P 500.

Dividends

FMC pays an annual dividend of $0.66 per share and has a dividend yield of 0.8%. Basf pays an annual dividend of $0.66 per share and has a dividend yield of 2.7%. FMC pays out 24.4% of its earnings in the form of a dividend. Basf pays out 36.3% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. FMC has increased its dividend for 7 consecutive years.

Insider & Institutional Ownership

84.5% of FMC shares are owned by institutional investors. Comparatively, 0.5% of Basf shares are owned by institutional investors. 1.2% of FMC shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares FMC and Basf’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
FMC $2.88 billion 4.05 $535.80 million $2.71 31.95
Basf $72.83 billion 1.22 $6.87 billion $1.82 13.29

Basf has higher revenue and earnings than FMC. Basf is trading at a lower price-to-earnings ratio than FMC, indicating that it is currently the more affordable of the two stocks.

Summary

FMC beats Basf on 13 of the 17 factors compared between the two stocks.

About FMC

FMC Corporation, a diversified chemical company, provides solutions, applications, and products for the agricultural, consumer, and industrial markets worldwide. The company operates in two segments, FMC Agricultural Solutions and FMC Lithium. The FMC Agricultural Solutions segment develops, manufactures, markets, and sells crop protection chemicals, including insecticides, herbicides, and fungicides that are used in agriculture to enhance crop yield and quality by controlling a range of insects, weeds, and diseases, as well as in non-agricultural markets for pest control. The FMC Lithium segment manufactures lithium for use in batteries, polymers, pharmaceuticals, greases and lubricants, glass and ceramics, and other industrial uses. FMC Corporation was founded in 1883 and is headquartered in Philadelphia, Pennsylvania.

About Basf

BASF SE operates as a chemical company worldwide. It operates through five segments: Chemicals, Performance Products, Functional Materials & Solutions, Agricultural Solutions, and Oil & Gas. The Chemicals segment offers solvents, plasticizers, monomers, and glues, as well as raw materials for detergents, plastics, textile fibers, paints and coatings, crop protection products, and medicines. The Performance Products segment provides dispersions and pigments, care chemicals, nutrition and health products, and performance chemicals that are used in pharmaceuticals, personal care products, and cosmetics, as well as hygiene and household products; and other products for enhancing processes in the paper industry and water treatment, as well as in oil, gas, and ore extraction. The Functional Materials & Solutions segment offers catalysts, battery materials, engineering plastics, polyurethane systems, automotive coatings, surface treatment solutions, and concrete admixtures; and tile adhesives and decorative paints for the automotive, electrical, chemical, and construction industries, as well as for household, and sports and leisure applications. The Agricultural Solutions segment provides fungicides, herbicides, and insecticides, as well as functional crop care products. The Oil & Gas segment explores for and produces oil and gas in Europe, North Africa, Russia, South America, and the Middle East. It also produces ammonia; and transports natural gas in Europe. BASF SE was founded in 1865 and is headquartered in Ludwigshafen am Rhein, Germany.

Wednesday, June 20, 2018

Top 10 Casino Stocks To Watch Right Now

tags:HASI,HSBC,WYNN,EXPD,CMO,TROV,NOAH,IJJ,TOWN,DCIX,

Perhaps it is because trading stocks can often mirror the thrill of winning big at the blackjack tables, or maybe it is because Las Vegas conjures images of the world’s most flashy brands and businessmen. Regardless of the reason, it is clear that gambling stocks are always among the most popular on Wall Street.

Luckily for investors, now is also a great time to be buying gambling stocks, as continued Vegas strength, a great recovery in Macau, and overall international interest in gaming have led to rising share prices. What’s more, the U.S. Supreme Court just overturned a decades-long ban on sports betting, opening the door for many new legal gambling avenues soon.

According to our Zacks Industry Rank data, the overall “Gaming” industry has gained more than 27.6% in the past year, outpacing the S&P 500’s respectable 15.9% gain. With casino stocks this hot right now, investors are not going to want to miss out.

Luckily, we can use Zacks’ proven stock-picking methods to find solid stocks in any industry. Check out these casino stocks today:

Top 10 Casino Stocks To Watch Right Now: Hannon Armstrong Sustainable Infrastructure Capital, Inc.(HASI)

Advisors' Opinion:
  • [By Lee Jackson]

    This is another solid value at current levels. Hannon Armstrong Sustainable Infrastructure Capital Inc. (NYSE: HASI) is a specialty finance company that directly originates debt and equity investments for sustainable infrastructure projects. The company��s projects focus on products that increase energy efficiency, offer cleaner energy sources and efficiently use natural resources.

  • [By Travis Hoium]

    I think three energy stocks --�TerraForm Power Inc (NASDAQ:TERP),�Hannon Armstrong Sustainable Infrastructure Capital Inc (NYSE:HASI), and AES Corp (NYSE:AES)�--�have what it takes to be great dividend stocks for investors looking to generate cash from their portfolios.�

Top 10 Casino Stocks To Watch Right Now: HSBC Holdings plc(HSBC)

Advisors' Opinion:
  • [By ]

    HSBC Plc (HSBC) shares were a notable mover, falling 3.04% to the bottom of the FTSE 100 in London, after Europe's biggest bank posted a weaker-than-expected set of first quarter earnings that raised questions about new focus on developing business in Asia under new CEO John Flint.

  • [By ]

    HSBC Holdings PLC (NYSE: HSBC)
    In order to grow, economies need capital. HSBC has it. With $2.52 trillion in total assets, HSBC holds the spot as the world��s seventh largest bank by total assets and is currently ranked as Europe��s largest bank. Covering the full gamut of financial services, from banking to wealth management to capital markets, HSBC��s international and emerging market focus make the bank the company to own going forward. Also, normalizing interest rates should benefit the company��s bottom line.

  • [By Lisa Levin]

    Check out these big penny stock gainers and losers

    Losers Fluor Corporation (NYSE: FLR) fell 13.4 percent to $51.10 in pre-market trading after the company reported downbeat earnings for its first quarter and lowered its profit outlook for the year. Integrated Media Technology Limited (NASDAQ: IMTE) fell 9.8 percent to $28.97 in pre-market trading after surging 46.29 percent on Thursday. Gogo Inc. (NASDAQ: GOGO) shares fell 8.2 percent to $8.81 in pre-market trading after the company reported Q1 results and disclosed that it is withdrawing its FY18 outlook for adjusted EBITDA, airborne cash capex, airborne equipment inventory purchases and free cash flow. Sharing Economy International Inc. (NASDAQ: SEII) shares fell 7.5 percent to $3.98 in pre-market trading after climbing 22.16 percent on Thursday. Arista Networks, Inc. (NYSE: ANET) fell 7.4 percent to $248.00 in pre-market trading following first-quarter earnings. Web.com Group, Inc. (NASDAQ: WEB) fell 6.7 percent to $18.00 in pre-market trading after reporting Q1 results. Varex Imaging Corporation (NASDAQ: VREX) fell 5.2 percent to $34 in pre-market trading after reporting Q2 results. Turkcell Iletisim Hizmetleri A.S. (NYSE: TKC) shares fell 5.2 percent to $7.60 in pre-market trading after dropping 3.02 percent on Thursday. AMN Healthcare Services, Inc (NYSE: AMN) shares fell 4.7 percent to $61.70 in pre-market trading following Q1 earnings. HSBC Holdings plc (NYSE: HSEA) fell 4.6 percent to $25.15 in pre-market trading after reporting Q1 results. Stratasys Ltd. (NASDAQ: SSYS) shares fell 4 percent to $16.66 in pre-market trading after dropping 2.86 percent on Thursday. Melco Resorts & Entertainment Limited (NASDAQ: MLCO) fell 4 percent to $30.65 in pre-market trading. Century Aluminum Co (NASDAQ: CENX) fell 4 percent to $15.76 in pre-market trading following Q1 results. HSBC Holdings plc (NYSE: HSBC) shares fell 3.5 percent to $48.10 in pre-market tr
  • [By Money Morning Staff Reports]

    Here's what you need to know.

    The Top Cryptocurrency Stories for May 14, 2018 China will soon release an official report on about 30 decentralized currencies. "This independent analysis of cryptocurrencies and global public blockchain technology demonstrates the confidence of the Chinese government in the technology, and will act as a guide," regulators said. Markets are also keeping an eye on Facebook Inc. (Nasdaq: FB). Last week, Cheddar reported that the social media giant is considering the creation of its own cryptocurrency. The development is surprising, given that the company had banned advertising related to cryptocurrencies earlier this year. The Facebook cryptocurrency would be used to facilitate payments on its platform. It's worth noting that the head of the group that is exploring the Facebook coin is a board member of the cryptocurrency exchange Coinbase. Will cryptocurrencies be part of a future bailout or economic stimulus effort by the U.S. Federal Reserve? That was suggested in new report by research analysts at Morgan Stanley (NYSE: MS). The Wall Street investment bank suggests that state-sponsored cryptocurrencies could allow central banks to press interest rates into negative territory. "Freely circulating paper notes and coins (cash) limits the ability of the central banks to force negative deposit rates," the report reads. "A digital version of cash could theoretically allow negative deposit rates to be charged on all money in circulation within any economy." Finally, markets are reacting positively to the announcement that ING Bank and HSBC Holdings Plc. (NYSE: HSBC) engaged in their first trade ever using blockchain technology. The two engaged in a trade on behalf of Cargill to finance a shipment of soybeans from Argentina to Malaysia. The Shocking Reason Why We Think Bitcoin Could Hit $100,000 (and How You Could Make Millions)

    Money Morning Defense and Tech Specialist – and cryptocurrency legend – Michael Robinson ju

Top 10 Casino Stocks To Watch Right Now: Wynn Resorts, Limited(WYNN)

Advisors' Opinion:
  • [By Rich Duprey]

    Although the idea MGM Resorts (NYSE:MGM) might step in to buy troubled Wynn Resorts (NASDAQ:WYNN) was always more speculative than based on any concrete evidence, the chances of it actually happening have now been reduced to virtually nil.

  • [By Garrett Baldwin]

    Markets are keeping a close eye on the 10-year bond, which is hovering near 3% – an important psychological level that is likely to influence future price movements. On Monday, Fox Business Network's "Varney & Co." asked Money Morning Chief Investment Strategist Keith Fitz-Gerald if investors should be worried. Here's what Keith had to say about the 10-year Treasury yield… and how it will affect your stocks and bonds in the future. The price of Brent crude oil topped $75.00 and hit its highest level since November 2014. Oil traders were eyeing the ongoing efforts of OPEC and Russia to reduce excessive production around the globe, rising demand ahead of peak driving season, and the possibility that the Trump administration will slap Iran with a new round of sanctions. Three Stocks to Watch Today: KO, GOOGL, SLM Shares of The Coca-Cola Co.�(NYSE: KO) added 1.2% after the firm easily beat earnings and revenue expectations. The firm cited strong demand for its new flavors of Diet Coke and its Coke Zero Sugar. Demand was so strong for the quarter that the firm reported organic sales growth of 5%. The company reported earnings per share of $0.47, topping estimates by a penny. Revenue of $7.6 billion easily beat Wall Street estimates. Shares of Alphabet Inc. (Nasdaq: GOOGL) seesawed in pre-market hours. The online search giant topped Wall Street earnings and revenue expectations after the bell Monday. However, shares were off 0.5% after executives announced that its business costs were on the rise. The firm's real estate and computer purchases tripled in one year, to $7.3 billion. About one-third of that total came from its $2.4 billion purchase of the Chelsea Market building in New York City. Good news for SLM Corp.�(NYSE: SLM) investors, but bad news for indebted college students and graduates. The firm – also known as Sallie Mae – topped Wall Street earnings expectations on Monday. The firm said that it increased its loan o
  • [By Chris Lange]

    The S&P 500 stock posting the largest daily percentage loss ahead of the close Monday was Wynn Resorts, Limited (NASDAQ: WYNN) which traded down roughly 9% at $163.45. The stock��s 52-week range is $92.67 to $203.63. Volume was about 26 million compared to the daily average volume of 2.2 million.

  • [By Travis Hoium]

    Wynn Resorts' (NASDAQ:WYNN) first quarterly report without founder Steve Wynn as CEO -- or even owning any shares of the casino resort operator -- went about as well as it could have. The sexual misconduct allegations against Steve Wynn don't seem to have caused any disruption to the business in the U.S., and Wynn Resorts continued to take market share from competitors in Macau.�

Top 10 Casino Stocks To Watch Right Now: Expeditors International of Washington, Inc.(EXPD)

Advisors' Opinion:
  • [By Joseph Griffin]

    Expeditors International of Washington (NASDAQ:EXPD) has been assigned a consensus recommendation of “Hold” from the eleven research firms that are covering the company, Marketbeat reports. Three analysts have rated the stock with a sell recommendation, five have given a hold recommendation and three have issued a buy recommendation on the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $65.63.

  • [By Lisa Levin] Companies Reporting Before The Bell Dean Foods Company (NYSE: DF) is projected to report quarterly earnings at $0.11 per share on revenue of $1.85 billion. Discovery, Inc. (NASDAQ: DISCA) is expected to report quarterly earnings at $0.44 per share on revenue of $1.99 billion. Jacobs Engineering Group Inc. (NYSE: JEC) is estimated to report quarterly earnings at $0.89 per share on revenue of $3.63 billion. Henry Schein, Inc. (NASDAQ: HSIC) is expected to report quarterly earnings at $0.92 per share on revenue of $3.17 billion. Gartner, Inc. (NYSE: IT) is projected to report quarterly earnings at $0.57 per share on revenue of $926.18 million. The AES Corporation (NYSE: AES) is estimated to report quarterly earnings at $0.24 per share on revenue of $2.98 billion. Expeditors International of Washington, Inc. (NASDAQ: EXPD) is projected to report quarterly earnings at $0.64 per share on revenue of $1.71 billion. US Foods Holding Corp. (NYSE: USFD) is expected to report quarterly earnings at $0.32 per share on revenue of $5.98 billion. DISH Network Corporation (NASDAQ: DISH) is expected to report quarterly earnings at $0.7 per share on revenue of $3.50 billion. Zebra Technologies Corporation (NASDAQ: ZBRA) is estimated to report quarterly earnings at $2.06 per share on revenue of $936.98 million. Camping World Holdings, Inc. (NYSE: CWH) is expected to report quarterly earnings at $0.42 per share on revenue of $1.06 billion. Perrigo Company plc (NYSE: PRGO) is projected to report quarterly earnings at $1.14 per share on revenue of $1.21 billion. Petróleo Brasileiro S.A. - Petrobras (NYSE: PBR) is estimated to report quarterly earnings at $0.28 per share on revenue of $23.80 billion. JD.com, Inc. (NYSE: JD) is projected to report quarterly earnings at $0.18 per share on revenue of $15.65 billion. Valeant Pharmaceuticals International, Inc. (NYSE: VRX) is projected to report quarterly earnings at $0.6 per share o
  • [By Dan Caplinger]

    Tuesday saw an up-and-down session on Wall Street, with major benchmarks trading on either side of the unchanged mark before finishing the day flat. Many investors kept most of their attention on Washington, where the White House announced that the U.S. would withdraw from the deal that the previous administration made with Iran concerning nuclear development. The withdrawal was largely expected, and although crude oil and other commodities were volatile leading up to the final decision, most other financial markets seemed prepared for the announcement. Even on a lackluster day, some companies had good news that lifted their shares substantially. Expeditors International of Washington (NASDAQ:EXPD), Valeant Pharmaceuticals International (NYSE:VRX), and SeaWorld Entertainment (NYSE:SEAS) were among the best performers on the day. Here's why they did so well.

  • [By Logan Wallace]

    Adviser Investments LLC trimmed its holdings in Expeditors International of Washington (NASDAQ:EXPD) by 78.8% in the first quarter, HoldingsChannel.com reports. The fund owned 2,550 shares of the transportation company’s stock after selling 9,500 shares during the period. Adviser Investments LLC’s holdings in Expeditors International of Washington were worth $161,000 at the end of the most recent quarter.

Top 10 Casino Stocks To Watch Right Now: Capstead Mortgage Corporation(CMO)

Advisors' Opinion:
  • [By Logan Wallace]

    Capstead Mortgage (NYSE:CMO) was downgraded by investment analysts at ValuEngine from a “hold” rating to a “sell” rating in a research report issued on Wednesday.

Top 10 Casino Stocks To Watch Right Now: TrovaGene, Inc.(TROV)

Advisors' Opinion:
  • [By Paul Ausick]

    TrovaGene Inc. (NASDAQ: TROV) fell more than 55% Friday to post a new 52-week low of $0.79 after closing at $1.77 on Thursday. The 52-week high is $19.56. Volume of around 11 million was nearly five times the daily average of about 230,000. The company announced a public offering of $18 million in stock and warrants priced at $1.00 for the unit.

  • [By Logan Wallace]

    TrovaGene Inc (NASDAQ:TROV) has been assigned a consensus rating of “Hold” from the six research firms that are currently covering the stock, Marketbeat reports. Four investment analysts have rated the stock with a hold recommendation and two have issued a buy recommendation on the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $7.00.

Top 10 Casino Stocks To Watch Right Now: Noah Holdings Ltd.(NOAH)

Advisors' Opinion:
  • [By Lisa Levin]

    Check out these big penny stock gainers and losers

    Losers Petróleo Brasileiro S.A. - Petrobras (NYSE: PBR) fell 13.2 percent to $10.95 in pre-market trading after dropping 1.33 percent on Friday. Banco Santander, S.A. (NYSE: SAN) shares fell 8.7 percent to $5.33 in pre-market trading after declining 2.83 percent on Friday. Synchrony Financial (NYSE: SYF) fell 8 percent to $32.75 in the pre-market trading session. AerCap Holdings N.V. (NYSE: AER) shares fell 7.4 percent to $51.17 in pre-market trading. Inovio Pharmaceuticals, Inc. (NASDAQ: INO) fell 7.4 percent to $4.54 in pre-market trading. Tailored Brands, Inc. (NYSE: TLRD) fell 7 percent to $31.83 in pre-market trading. California Resources Corporation (NYSE: CRC) shares fell 6.5 percent to $30.29 in pre-market trading after dropping 10.60 percent on Friday. Manhattan Bridge Capital, Inc. (NASDAQ: LOAN) fell 6.2 percent to $6.85 in pre-market trading. RedHill Biopharma Ltd. (NASDAQ: RDHL) fell 6 percent to $6.67 in pre-market trading. QEP Resources, Inc. (NYSE: QEP) shares fell 5.8 percent to $11.45 in pre-market trading after dropping 6.75 percent on Friday. Noah Holdings Limited (NYSE: NOAH) fell 5.5 percent to $61.53 in pre-market trading. CNH Industrial N.V. (NYSE: CNHI) shares fell 5.2 percent to $11.70 in pre-market trading
  • [By Max Byerly]

    Noah (NYSE:NOAH) was downgraded by analysts at Nomura from a buy rating to a neutral rating.

    TherapeuticsMD (NASDAQ:TXMD) was given a $12.00 price target by analysts at Oppenheimer Holdings Inc.. The firm currently has a buy rating on the stock.

  • [By Shane Hupp]

    Noah (NYSE: NOAH) and MAN Grp PLC/ADR (OTCMKTS:MNGPY) are both mid-cap finance companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, analyst recommendations, dividends, valuation, risk, institutional ownership and earnings.

  • [By Joseph Griffin]

    Noah Coin (CURRENCY:NOAH) traded up 4% against the US dollar during the 1 day period ending at 23:00 PM E.T. on May 18th. During the last seven days, Noah Coin has traded down 6.4% against the US dollar. One Noah Coin token can now be purchased for about $0.0079 or 0.00000096 BTC on exchanges. Noah Coin has a market cap of $0.00 and $4.58 million worth of Noah Coin was traded on exchanges in the last day.

Top 10 Casino Stocks To Watch Right Now: iShares S&P Mid-Cap 400 Value (IJJ)

Advisors' Opinion:
  • [By Joseph Griffin]

    D.A. Davidson & CO. lifted its stake in iShares S&P Mid-Cap 400 Value ETF (NYSEARCA:IJJ) by 5.0% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 170,056 shares of the company’s stock after buying an additional 8,024 shares during the quarter. D.A. Davidson & CO.’s holdings in iShares S&P Mid-Cap 400 Value ETF were worth $26,274,000 as of its most recent SEC filing.

  • [By Joseph Griffin]

    Cullen Frost Bankers Inc. reduced its stake in Ishares Trust S & P Mid Capital* (NYSEARCA:IJJ) by 73.5% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 23,648 shares of the company’s stock after selling 65,628 shares during the period. Cullen Frost Bankers Inc. owned 0.06% of Ishares Trust S & P Mid Capital* worth $3,654,000 as of its most recent SEC filing.

Top 10 Casino Stocks To Watch Right Now: Towne Bank(TOWN)

Advisors' Opinion:
  • [By Joseph Griffin]

    John W. Rosenthal Capital Management Inc. grew its stake in shares of TowneBank (NASDAQ:TOWN) by 10.0% in the first quarter, HoldingsChannel.com reports. The firm owned 110,000 shares of the bank’s stock after buying an additional 10,000 shares during the quarter. TowneBank comprises approximately 2.5% of John W. Rosenthal Capital Management Inc.’s holdings, making the stock its 16th largest holding. John W. Rosenthal Capital Management Inc.’s holdings in TowneBank were worth $3,146,000 as of its most recent filing with the SEC.

Top 10 Casino Stocks To Watch Right Now: Diana Containerships Inc.(DCIX)

Advisors' Opinion:
  • [By Lisa Levin] Gainers Carver Bancorp, Inc. (NASDAQ: CARV) shares jumped 92.1 percent to $7.01. iPic Entertainment Inc. (NASDAQ: IPIC) gained 21.6 percent to $9.73. Baozun Inc. (NASDAQ: BZUN) shares jumped 18.7 percent to $53.49 after reporting Q1 results. World Wrestling Entertainment, Inc. (NYSE: WWE) shares jumped 15.9 percent to $50.50. The company's "Smackdown Live" may not be renewed at NBCUniversal network and the company's "Monday Night Raw" program could be worth three times its current value elsewhere, according to a report for The Hollywood Reporter. Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) gained 14.7 percent to $ 20.46 after the company issued further details on Phase 3 ADVANCE study of ROLONTIS. Motus GI Holdings, Inc. (NASDAQ: MOTS) climbed 13.4 percent to $5.5009. Endocyte, Inc. (NASDAQ: ECYT) rose 13.3 percent to $ 14.23 after the company announced presentation of Phase 2 data from prostate cancer trial of 177Lu-PSMA-617 at the 2018 ASCO Annual Meeting. Diana Containerships Inc. (NASDAQ: DCIX) gained 12.9 percent to $1.7499 after the company announced the sale of Post-Panamax Container Vessel for $21 million. Essendant Inc. (NASDAQ: ESND) gained 12.7 percent to $12.43. Essendant confirmed receipt of unsolicited proposal from Staples of $11.50 per share in cash. Blink Charging Co (NASDAQ: BLNK) rose 11.8 percent to $8.04 after surging 31.68 percent on Wednesday. OptimumBank Holdings, Inc. (NASDAQ: OPHC) gained 11.5 percent to $5.15. Flotek Industries, Inc. (NYSE: FTK) shares climbed 10.7 percent to $3.74. Farmer Bros. Co. (NASDAQ: FARM) rose 7.9 percent to $25.95 after climbing 7.90 percent on Wednesday. Minerva Neurosciences Inc (NASDAQ: NERV) rose 6.5 percent to $6.93 after Journal of Clinical Psychiatry published positive results of cognitive performance from Phase 2B trial of roluperidone in schizophrenia patients. Williams Partners L.P. (NYSE: WPZ) rose 5.6 percent to $40

Wednesday, May 30, 2018

Bruker (BRKR) Expected to Announce Quarterly Sales of $434.72 Million

Brokerages expect Bruker (NASDAQ:BRKR) to report sales of $434.72 million for the current quarter, Zacks Investment Research reports. Six analysts have issued estimates for Bruker’s earnings, with estimates ranging from $427.50 million to $444.00 million. Bruker posted sales of $414.90 million in the same quarter last year, which suggests a positive year-over-year growth rate of 4.8%. The firm is scheduled to issue its next quarterly earnings report on Thursday, August 2nd.

On average, analysts expect that Bruker will report full-year sales of $1.89 billion for the current year, with estimates ranging from $1.89 billion to $1.90 billion. For the next financial year, analysts forecast that the company will report sales of $1.96 billion per share, with estimates ranging from $1.95 billion to $1.98 billion. Zacks’ sales calculations are an average based on a survey of research analysts that that provide coverage for Bruker.

Get Bruker alerts:

Bruker (NASDAQ:BRKR) last released its earnings results on Thursday, May 3rd. The medical research company reported $0.24 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.22 by $0.02. Bruker had a net margin of 4.63% and a return on equity of 27.04%. The firm had revenue of $431.70 million during the quarter, compared to the consensus estimate of $419.25 million. During the same period in the prior year, the firm earned $0.19 EPS. The company’s revenue was up 12.2% compared to the same quarter last year.

BRKR has been the subject of several analyst reports. Morgan Stanley cut their price objective on shares of Bruker from $32.00 to $31.00 and set an “equal weight” rating for the company in a report on Wednesday, April 11th. BidaskClub downgraded shares of Bruker from a “buy” rating to a “hold” rating in a report on Saturday, February 10th. Leerink Swann raised their price objective on shares of Bruker from $32.00 to $34.00 and gave the stock a “market perform” rating in a report on Friday, February 9th. Bank of America cut their price objective on shares of Bruker from $37.00 to $34.00 and set a “neutral” rating for the company in a report on Friday, May 4th. Finally, Zacks Investment Research upgraded shares of Bruker from a “hold” rating to a “buy” rating and set a $34.00 target price on the stock in a research note on Tuesday, May 8th. Two equities research analysts have rated the stock with a sell rating, eight have given a hold rating and three have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average price target of $32.91.

Bruker traded down $0.27, hitting $30.11, on Friday, according to MarketBeat Ratings. The company’s stock had a trading volume of 13,993 shares, compared to its average volume of 629,457. The company has a market cap of $4.74 billion, a PE ratio of 24.88, a price-to-earnings-growth ratio of 2.00 and a beta of 1.14. Bruker has a 12 month low of $26.76 and a 12 month high of $36.53. The company has a current ratio of 2.22, a quick ratio of 1.29 and a debt-to-equity ratio of 0.26.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 22nd. Stockholders of record on Monday, June 4th will be given a dividend of $0.04 per share. This represents a $0.16 annualized dividend and a dividend yield of 0.53%. The ex-dividend date is Friday, June 1st. Bruker’s dividend payout ratio (DPR) is currently 13.22%.

A number of large investors have recently modified their holdings of the stock. BlackRock Inc. raised its position in Bruker by 1.8% in the 1st quarter. BlackRock Inc. now owns 5,267,689 shares of the medical research company’s stock worth $157,609,000 after purchasing an additional 93,829 shares during the period. Russell Investments Group Ltd. raised its position in Bruker by 1.3% in the 1st quarter. Russell Investments Group Ltd. now owns 1,483,860 shares of the medical research company’s stock worth $44,397,000 after purchasing an additional 19,226 shares during the period. Boston Partners raised its position in Bruker by 2.7% in the 1st quarter. Boston Partners now owns 1,297,471 shares of the medical research company’s stock worth $38,821,000 after purchasing an additional 34,578 shares during the period. Geode Capital Management LLC raised its position in Bruker by 2.5% in the 4th quarter. Geode Capital Management LLC now owns 1,294,131 shares of the medical research company’s stock worth $44,414,000 after purchasing an additional 31,742 shares during the period. Finally, Dimensional Fund Advisors LP raised its position in Bruker by 1.9% in the 1st quarter. Dimensional Fund Advisors LP now owns 958,525 shares of the medical research company’s stock worth $28,679,000 after purchasing an additional 17,812 shares during the period. Institutional investors own 65.55% of the company’s stock.

About Bruker

Bruker Corporation manufactures and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates in two segments, Bruker Scientific Instruments, and Bruker Energy & Supercon Technologies. It offers life science tools based on magnetic resonance technology; life science mass spectrometry and ion mobility spectrometry systems; infrared spectroscopy and radiological/nuclear detectors for chemical, biological, radiological, nuclear, and explosive detection in emergency response, homeland security, and defense applications; and research, analytical, and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technologies.

Get a free copy of the Zacks research report on Bruker (BRKR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Bruker (NASDAQ:BRKR)

Sunday, May 27, 2018

$206.36 Million in Sales Expected for BlackBerry Ltd (BB) This Quarter

Equities analysts expect BlackBerry Ltd (NYSE:BB) to report $206.36 million in sales for the current quarter, according to Zacks. Two analysts have issued estimates for BlackBerry’s earnings. The lowest sales estimate is $200.72 million and the highest is $212.00 million. BlackBerry reported sales of $244.00 million during the same quarter last year, which would suggest a negative year over year growth rate of 15.4%. The company is expected to report its next earnings report on Friday, June 22nd.

According to Zacks, analysts expect that BlackBerry will report full-year sales of $880.29 million for the current year, with estimates ranging from $856.14 million to $894.00 million. For the next fiscal year, analysts forecast that the business will report sales of $940.27 million per share, with estimates ranging from $922.78 million to $953.00 million. Zacks Investment Research’s sales averages are a mean average based on a survey of analysts that cover BlackBerry.

Get BlackBerry alerts:

BlackBerry (NYSE:BB) last released its quarterly earnings data on Wednesday, March 28th. The company reported $0.03 EPS for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.06. The firm had revenue of $239.00 million during the quarter, compared to the consensus estimate of $217.88 million. BlackBerry had a net margin of 43.46% and a return on equity of 3.70%. The business’s quarterly revenue was down 16.4% on a year-over-year basis.

BB has been the topic of a number of recent research reports. Vetr upgraded BlackBerry from a “sell” rating to a “hold” rating and set a $10.20 target price on the stock in a research note on Monday, April 9th. Canaccord Genuity reiterated a “hold” rating and issued a $11.00 target price on shares of BlackBerry in a research note on Thursday, March 29th. Raymond James reiterated a “market perform” rating and issued a $11.00 target price on shares of BlackBerry in a research note on Thursday, March 29th. MKM Partners raised their target price on BlackBerry and gave the company a “neutral” rating in a research note on Thursday, March 29th. Finally, Zacks Investment Research upgraded BlackBerry from a “hold” rating to a “strong-buy” rating and set a $12.00 target price on the stock in a research note on Tuesday, April 3rd. Four investment analysts have rated the stock with a sell rating, ten have given a hold rating, four have issued a buy rating and one has issued a strong buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average price target of $10.80.

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Iridian Asset Management LLC CT bought a new stake in shares of BlackBerry during the first quarter valued at about $165,353,000. Ontario Teachers Pension Plan Board bought a new stake in shares of BlackBerry during the first quarter valued at about $119,413,000. Royal Bank of Canada bought a new stake in shares of BlackBerry during the first quarter valued at about $80,818,000. CIBC World Markets Inc. bought a new stake in shares of BlackBerry during the first quarter valued at about $67,346,000. Finally, First Eagle Investment Management LLC bought a new stake in shares of BlackBerry during the first quarter valued at about $54,613,000. Institutional investors and hedge funds own 57.58% of the company’s stock.

BlackBerry stock traded up $0.18 during mid-day trading on Tuesday, reaching $11.75. The company’s stock had a trading volume of 2,418,500 shares, compared to its average volume of 5,557,430. The company has a market cap of $6.23 billion, a PE ratio of 235.00 and a beta of 1.10. The company has a debt-to-equity ratio of 0.31, a current ratio of 5.49 and a quick ratio of 5.48. BlackBerry has a twelve month low of $8.47 and a twelve month high of $14.55.

About BlackBerry

BlackBerry Limited operates as an enterprise software and services company focused on securing and managing endpoints in the Internet of Things. It offers BlackBerry Enterprise Mobility Suite, which combines and integrates mobile security, management, productivity, and collaboration solutions, such as BlackBerry UEM, BlackBerry Dynamics, and BlackBerry Workspaces; BlackBerry AtHoc, a secure and networked crisis communications solution; SecuSUITE for Government, a voice encryption software solution; BlackBerry Enterprise Consulting and BlackBerry Cybersecurity Consulting; and BBM Enterprise, an enterprise-grade secure instant messaging solution, as well as Communications Platform as a Service.

Get a free copy of the Zacks research report on BlackBerry (BB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for BlackBerry (NYSE:BB)

Saturday, May 26, 2018

Reader Inquiry: Could Protagonist Therapeutics Rebound In The Near Term?

Shares of Protagonist Therapeutics (PTGX) have lost over two-thirds of their value year to date. The stock popped up on my radar after noticing several green flags, including institutional positioning and a key executive hire.

Chart

Figure 1: PTGX daily advanced chart (source: Finviz)

Figure 2: PTGX 15-minute chart (source: Finviz)

When looking at charts, clarity often comes from taking a look at distinct time frames in order to determine important technical levels and get a feel for what's going on. In the first chart (daily advanced), we can see the huge gap down in March after negative clinical news was announced. In the second chart (15-minute), we can see the makings of a nice rebound underway with the stock likely to rebound at least to where it originally was above the $8 level.

Reader Inquiry

In the marketplace service ROTY (Runners of the Year), we search for stocks that are attractive across multiple time frames with potential for high percentage upside within the near to medium term.

Late last week in ROTY, I published an update piece on an under the radar potential ASCO winner. A few days ago, in the model account, we added two key positions with catalysts coming up in the second half of the year.

Figure 3: Pipeline (source: corporate website)

In the case of Protagonist Therapeutics, in ROTY Live Chat I pointed out several green flags to members yesterday. My objective now is to find out whether this one could rebound significantly in the near term and if it can potentially become our newest ROTY Contender.

Recent Developments

The stock price plunged in late March after the company announced disappointing news for their lead asset PTG-100, an oral GI-restricted alpha-4-beta-7 integrin antagonist peptide. In the phase 2b PROPEL trial, PTG-100 was being evaluated for use in patients with moderate to severe ulcerative colitis.

This was a potentially lucrative indication, a clinically validated target (multi-billion-dollar market opportunity) where an oral peptide would be a welcome alternative to injectable monoclonal antibodies. Treatments such as REMICADE and HUMIRA dominate targeted therapy for the IBD market with sales set to hit $21 billion by 2020. Unfortunately, setbacks such as low response rates, safety concerns, and lack of convenience represent major obstacles for such treatments. On paper, an investment in the company made sense, as their peptides held promise to address those obstacles and potentially transform the market by introducing targeted therapy to patients with mild-to-moderate disease and potentially being combined with other oral agents.

Figure 4: Blockbuster market opportunity snapshot (source: corporate presentation)

Unfortunately, the company announced discontinuation of the PROPEL study following an interim analysis by an independent Data Monitoring Committee of unblinded efficacy and safety data for the first 65 patients out of the 240 total the company wished to enroll. The DMC decided the trial wasn't worth continuing based on analysis of the primary endpoint of clinical remission. Importantly, there were no safety issues noted. However, a usually high placebo response was surprising.

As a result, the company also decided to postpone their decision concerning initiation of the phase 2/3 study in chronic pouchitis until after a full review of the interim data from the PROPEL study. Said review should be finished up in the third quarter.

If they do by chance decide to go ahead with the late-stage study, chronic pouchitis represents an attractive rare disease indication with around 20,000 patients in the United States and as many in Europe.

In mid-May, the company announced clinical and preclinical abstracts for PTG-300, their injectable hepcidin mimetic being evaluated for treatment of anemia and iron overload in rare blood disorders, had been accepted for oral presentation at the 23rd Congress of the European Hematology Association. The meeting takes place June 14th through the 17th and perhaps this catalyst could help the stock bounce back in the near term.

On May 24th, I came across two major green flags - one was the appointment of Samuel Saks, M.D., as Chief Development Officer. He will be in charge of the company's R&D efforts. It merits pointing out that prior he served in the same role at Auspex Pharmaceuticals until it was acquired by Teva Pharmaceuticals (TEVA) for $3.5 billion. He also was co-founder of Jazz Pharmaceuticals (JAZZ). Long-time ROTY readers will recall that key executive hirings are an indicator we keep close tabs on.

The news also just came out that Biotechnology Value Fund has acquired a 6.9% stake in the company (or rather raised their stake considerably). Interest by key institutional players is another green flag we look out for.

Other Information

For the first quarter of 2018, the company reported cash and equivalents of $140.5 million, meaning their once promising platform is being valued at next to nothing currently. Management is guiding for an operational runway through 2019. Net loss for the period came in lower at $7.7 million while R&D expenses increased to $15.4 million. License and collaboration revenue totaled $10.8 million (revenue from activities performed under the Janssen Collaboration Agreement).

Speaking of which, the Janssen deal inked in May of last year merits highlighting. The collaboration is for co-development and commercialization of PTG-200, Protagonist's first-in-class, oral peptide IL-23 receptor antagonist. Keep in mind that Johnson & Johnson (JNJ) participated prior in a Series B financing for the smaller firm. Terms were attractive, with a $50 million upfront payment and milestones of up to $940 million (including significant development milestones for completion of the phase 2a/phase 2b study in Crohn's disease if Jansen chooses to keep its license after each event). Protagonist also is due double-digit tiered royalties on net product sales, later on, should they make it to approval.

Figure 4: Milestone breakdown from JNJ partnership (source: corporate presentation)

Dosing for all cohorts has been finished up in the phase 1 study in normal healthy volunteers (single-ascending and multiple-ascending doses). In the second half of the year, an IND filing in the US should pave the way for a global phase 2 study in Crohn's disease.

As for PTG-300 mentioned further above, an IND filing should be submitted in the third quarter to allow for initiation of a phase 2 study in beta-thalassemia patients in the fourth quarter. Later on, the company plans to explore other indications including treatment of anemia and transfusion-dependence in myelodysplastic syndromes and exaggerated erythropoiesis in polycythemia vera.

As for institutional investors of note, it's worth noting that EcoR1 Capital owns a new stake of over 1 million shares as well.

Final Thoughts

I'd like to close by referring back to BMO's analyst rating from early March, in which they placed an Outperform rating on shares and a $42 price target. The analyst stated the following (my emphasis in bold):

Low risk pipeline is quickly maturing with an interim analysis (futility) of the Phase 2b UC trial of PTG-100 later this month and final data in 4Q18. In addition, they expect advancement of PTG-200 into a Phase 2 Crohn's disease trial and start of PTG-300 trials in beta thalassemia in 2H18.

This is not to point fingers - I have my share of losers as well. It's to remind readers of two things, first that biotech is a minefield and the unexpected will happen from time to time. All we can do is manage risk the best we possibly can, so we'll be able to recover from such situations.

Secondly, other value drivers mentioned in that thesis are still intact for the latter two assets.

Perhaps after the steep decline, the present share price is an attractive entry point, considering the firm's cash position and insanely low valuation. In the near term, catalysts mentioned above could help to turn the situation around.

As for risks, there's always the possibility that the firm continues to burn cash without achieving success, resulting in further dilution down the road or worse. Nixing their lead program is possible, as is disappointing data and clinical setbacks (including delays) for their latter two programs or also the possibility of JNJ opting out.

I won't be adding this one to the ROTY Contenders List currently, as it merits more digging and I don't feel I have an advantage yet. That said, I look forward to coming catalysts and will continue to reevaluate. As stated before, the hiring of a high-profile executive and recent institutional positioning are two green flags to make this one worth following.

Keep in mind that when a stock is selected for ROTY, the corresponding article appears only to current subscribers. Also, for the purposes of due diligence, subscribers are able to access all of my archived work (getting around the 10-day paywall).

Disclaimer: Commentary presented is NOT individualized investment advice. Opinions offered here are NOT personalized recommendations. Readers are expected to do their own due diligence or consult an investment professional if needed prior to making trades. Strategies discussed should not be mistaken for recommendations, and past performance may not be indicative of future results. Although I do my best to present factual research, I do not in any way guarantee the accuracy of the information I post. I reserve the right to make investment decisions on behalf of myself and affiliates regarding any security without notification except where it is required by law. Keep in mind that any opinion or position disclosed on this platform is subject to change at any moment as the thesis evolves. Investing in common stock can result in partial or total loss of capital. In other words, readers are expected to form their own trading plan, do their own research, and take responsibility for their own actions. If they are not able or willing to do so, better to buy index funds or find a thoroughly vetted fee-only financial advisor to handle your account.

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Thursday, May 24, 2018

Puerto Rico's Surplus to Drop by $660 Million in Revised Plan

Puerto Rico’s forecast for its budget surplus over the next six years will be cut by $660 million because of the revisions to the plan for pulling the bankrupt island out of a decade-long recession.

The federal board and Governor Ricardo Rossello Sunday reached an agreement to scale back proposed labor reforms, such as ending Christmas bonuses, that the panel was pushing for in the island’s multi-year fiscal plan. That will cost Puerto Rico $660 million through fiscal 2023 and reduce its surplus over the next 30 years to $35 billion from $39 billion, Natalie Jaresko, the board’s executive director, said in a call Wednesday with reporters.

Jaresko has said the agreement with the governor was necessary to push ahead with reforms to increase business investment on the island and make Puerto Rico more competitive.

“This is all being done specifically focused on ensuring that structural reforms have less risk of implementation, there’s more certainty of them and the economic future of Puerto Rico and its financial capacity,” Jaresko said.

While the smaller surplus means less money to repay bondholders, the agreement prevented a legal fight between the oversight board and the island that could have delayed any recovery. How much of the $74 billion of debt is repaid will depend on the outcome of negotiations in bankruptcy court.

While it’s not certain that all of Puerto Rico’s surplus will go to bondholders, the amount does show the island’s capacity to repay, Jaresko said.

“It doesn’t mean that every dollar will go into any particular use but it is what defines to a large extent what is possible,” Jaresko said.

LISTEN TO ARTICLE 1:36 Share Share on Facebook Post to Twitter Send as an Email Print

Wednesday, May 23, 2018

CDK Global (CDK) Getting Somewhat Favorable Press Coverage, Report Finds

Media stories about CDK Global (NASDAQ:CDK) have trended somewhat positive on Tuesday, Accern Sentiment Analysis reports. The research firm identifies positive and negative press coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. CDK Global earned a news sentiment score of 0.09 on Accern’s scale. Accern also assigned media coverage about the software maker an impact score of 46.9002952818769 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

These are some of the headlines that may have effected Accern Sentiment’s analysis:

Get CDK Global alerts: CDK announces Connected Workshop concept (am-online.com) CDK Global announces new Connected Workshop concept (cardealermagazine.co.uk) Judge: Car dealer software companies can’t delete antitrust claims over monopolization of car dealer data (cookcountyrecord.com) CDK Global (CDK) vs. Ritchie Bros. Auctioneers (RBA) Head-To-Head Survey (americanbankingnews.com) $578.44 Million in Sales Expected for CDK Global (CDK) This Quarter (americanbankingnews.com)

CDK has been the subject of a number of research analyst reports. Barrington Research restated a “hold” rating on shares of CDK Global in a research note on Monday, March 26th. BidaskClub lowered shares of CDK Global from a “sell” rating to a “strong sell” rating in a research note on Wednesday, February 21st. Zacks Investment Research lowered shares of CDK Global from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, April 3rd. Morgan Stanley lifted their price target on shares of CDK Global from $76.00 to $77.00 and gave the stock an “equal weight” rating in a research note on Wednesday, January 31st. Finally, Wells Fargo restated an “outperform” rating and issued a $80.00 price target (up previously from $75.00) on shares of CDK Global in a research note on Wednesday, January 31st. Two investment analysts have rated the stock with a sell rating, three have given a hold rating and two have given a buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $74.80.

Shares of CDK Global traded down $0.17, hitting $63.26, during midday trading on Tuesday, according to MarketBeat Ratings. 759,500 shares of the stock traded hands, compared to its average volume of 1,166,587. CDK Global has a 1-year low of $59.33 and a 1-year high of $76.04. The company has a market cap of $8.42 billion, a price-to-earnings ratio of 26.03, a price-to-earnings-growth ratio of 1.98 and a beta of 0.77. The company has a debt-to-equity ratio of -9.65, a quick ratio of 1.80 and a current ratio of 1.80.

CDK Global (NASDAQ:CDK) last announced its quarterly earnings results on Thursday, April 26th. The software maker reported $0.85 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.84 by $0.01. CDK Global had a net margin of 14.99% and a negative return on equity of 361.64%. The company had revenue of $576.60 million during the quarter, compared to the consensus estimate of $578.11 million. During the same quarter in the previous year, the company posted $0.65 earnings per share. The company’s revenue for the quarter was up 3.6% compared to the same quarter last year. analysts predict that CDK Global will post 3.23 EPS for the current year.

In related news, EVP Scott L. Mathews sold 5,514 shares of the company’s stock in a transaction dated Wednesday, February 21st. The shares were sold at an average price of $68.91, for a total value of $379,969.74. Following the completion of the sale, the executive vice president now owns 48,520 shares of the company’s stock, valued at $3,343,513.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Rajiv K. Amar sold 1,968 shares of the company’s stock in a transaction dated Thursday, February 22nd. The stock was sold at an average price of $69.85, for a total transaction of $137,464.80. Following the completion of the sale, the insider now directly owns 11,072 shares of the company’s stock, valued at approximately $773,379.20. The disclosure for this sale can be found here. Corporate insiders own 0.39% of the company’s stock.

About CDK Global

CDK Global, Inc provides integrated information technology and digital marketing solutions to the automotive retail and other industries worldwide. The company operates through Retail Solutions North America, Advertising North America, and CDK International segments. It offers technology-based solutions, including automotive Website platforms; and advertising solutions comprising the management of digital advertising spend for original equipment manufacturers and automotive retailers.

Insider Buying and Selling by Quarter for CDK Global (NASDAQ:CDK)

Monday, May 21, 2018

How One Company Is Capitalizing On Cannabis Distillates' Surging Popularity

As Benzinga recently detailed, smoking is just one of many ways to consume cannabis. In fact, smoking is becoming less popular as other smokeless options continue to emerge. They include distillates, a kind of cannabis concentrate found in some vape pens or sold for use with dab rigs.

Much has been said about companies capitalizing on the smokeless cannabis consumption trend, but the focus is usually on the businesses making the actual distillates.

Little has been said about those “selling pickaxes,” those making the equipment needed to make the distillates in question. Benzinga reached out to Root Sciences, the largest cannabis distillery equipment maker in the United States and the producer of the Short Path Distillation system, which is used to make distillates containing tetrahydrocannabinol, cannabidiol and other cannabinoids.

How Short Path Distillation Works

How does Root Sciences’ distillation technology work and how is it different from others in the market?

The company’s equipment “rapidly puts the cannabis oil in its final stage,” with 60-percent THC potency and no impurities, CEO Nenad Yashruti told Benzinga.

“From the medical patient to the recreational consumer, concentrates of this purity, potency and consistency will be the cornerstone of future cannabis consumption,” Yashruti said in an interview with Dope Magazine in 2016.

Interestingly enough, this statement remains valid to date.

Related Link: Marijuana In College: Why Universities Are Offering Cannabis-Focused Classes (And Where You Can Find Them)

The Root Sciences Story

How did Root Sciences become a leader in the distillation equipment space?

Everything started in 2016, in Belfair, Washington.

“We had our sights set on ancillary parts of the business and knew we needed to be a practitioner first. We ended up building a state-of-the-art, first-of-its-kind facility that was featured in many industry publications and really established our management team as thought leaders in the industry,” Yashruti said in a conversation with Edibles Magazine.

In 2017, the company was using a short path, whipped film, molecular separation process, something other industries had been using for some time. Seeing an opportunity to build on the burgeoning market, Root Sciences stuck a deal with German equipment manufacturer VTA, a specialist in thermal process engineering.

“When we brought them out here [to our facility], they were impressed with the technology that we were using in all parts of cannabis,” Yashruti said. “They awarded us an exclusive distribution contract in North America for two years.”

The relationship exceeded expectations in just under six months, he said.

“We had so much success and became very close with a manufacturer that they extended the contract for a decade long and make it global. We are now the global exclusive distributor for VTA and the cannabis industry when it comes to purification plants.”

Root Sciences’ equipment now sells for more than $100,000 a set. “Our equipment is the most expensive, but it is by far better than anything on the market as it is being designed and updated continuously where other older technology systems have stagnated,” Yashruti said.

“Gone will be the days of making shatter or sugar concentrates that have to be individually weighed, packaged and processed,” Mr. Yashruti told Dope. “With distillate being in a liquid form, automation in the concentrate and edible market will be the clear winner. As more competitors pile into this industry, the lack of automation will be terminal.”

With the industry asking questions and market demand rising, Root Sciences' long strategy is paying off. Where it could go from here may only be limited by which markets open in the coming years. Stay tuned in for updates on this growing business.

Related Link:

Pot Stocks, ETFs, Top News And Data From The Cannabis Industry This Week 

Public domain photo via Wikimedia.